|Awarded On||May 20, 2015|
|Title||Drug Conjugates of anti-LGR5 Antibodies as Novel Therapeutics for Destroying Cancer Stem Cells|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Kendra Carmon|
|Cancer Sites||Colorectal, Gallbladder, Liver and Intrahepatic Bile Duct, Ovary, Small Intestine|
Research has shown that within several different malignant tumors types there exists a subpopulation of cancer cells that behave like normal stem cells. These cancer stem-like cells (CSCs) can renew themselves and sustain the cancer, much like normal stem cells repopulate and maintain our organs and tissues. CSCs can drive tumor growth, metastasis, and resistance to anti-cancer therapies. Since CSCs are often not entirely eliminated by conventional treatments, they can regenerate the tumor and potentially metastasize, leading to a decline in patient survival. Thus it is essential to develop a new generation of therapies that can target and destroy CSCs. The LGR5 receptor resides at low level...